Glicastar-M 80/500 Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The synergistic action of these two agents helps achieve better blood glucose regulation in patients inadequately controlled by diet and exercise alone. Glicastar-M is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, with a risk of hypoglycemia mainly attributed to Gliclazide. Regular monitoring of blood glucose levels, renal function, and periodic assessment of hematological parameters are recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerance. Glicastar-M should be used under medical supervision to optimize glycemic control and minimize complications associated with diabetes.